American Journal of Cardiology
Volume 104, Issue 10 , Pages 1357-1361 , 15 November 2009

Effectiveness of Two-Year Clopidogrel + Aspirin in Abolishing the Risk of Very Late Thrombosis After Drug-Eluting Stent Implantation (from the TYCOON [Two-Year ClOpidOgrel Need] Study)

  • Gaetano Tanzilli, MD

      Affiliations

    • Department of Heart and Great Vessels “Attilio Reale,” La Sapienza University, Rome, Italy
    • ,
  • Cesare Greco, MD

      Affiliations

    • Department of Heart and Great Vessels “Attilio Reale,” La Sapienza University, Rome, Italy
    • ,
  • Francesco Pelliccia, MD, PhD

      Affiliations

    • Department of Heart and Great Vessels “Attilio Reale,” La Sapienza University, Rome, Italy
    • Department of Cardiovascular Medicine, San Filippo Neri Hospital, Rome, Italy
    • Corresponding Author InformationCorresponding author: Tel: 39-348-339-2006; fax: 39-06-330-62516
    • ,
  • Vincenzo Pasceri, MD, PhD

      Affiliations

    • Department of Cardiovascular Medicine, San Filippo Neri Hospital, Rome, Italy
    • ,
  • Francesco Barillà, MD

      Affiliations

    • Department of Heart and Great Vessels “Attilio Reale,” La Sapienza University, Rome, Italy
    • ,
  • Vincenzo Paravati, MD

      Affiliations

    • Department of Heart and Great Vessels “Attilio Reale,” La Sapienza University, Rome, Italy
    • ,
  • Gaetano Pannitteri, MD

      Affiliations

    • Department of Heart and Great Vessels “Attilio Reale,” La Sapienza University, Rome, Italy
    • ,
  • Carlo Gaudio, MD

      Affiliations

    • Department of Heart and Great Vessels “Attilio Reale,” La Sapienza University, Rome, Italy
    • ,
  • Enrico Mangieri, MD

      Affiliations

    • Department of Heart and Great Vessels “Attilio Reale,” La Sapienza University, Rome, Italy

Received 25 May 2009 ,Revised 2 July 2009 ,Accepted 2 July 2009.

References 

  1. King SB, Smith SC, Hirshfeld JW, Jacobs AK, Morrison DA, Williams DO, et al. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol. 2008;51:172–209
  2. Banerjee S, Varghese C, Samule J, Banerjee S, Varghese C, Samuel J, et al. Comparison of the impact of short (<1 year) and long term (> or =1 year) clopidogrel use following percutaneous coronary intervention on mortality. Am J Cardiol. 2008;102:1159–1162
  3. Butler MJ, Eccleston D, Clark DJ, Butler MJ, Eccleston D, Clark DJ, et al. The effect of intended duration of clopidogrel use on early and late mortality and major adverse cardiac events in patients with drug-eluting stents. Am Heart J. 2009;157:899–907
  4. Maisel WH. Unanswered questions; drug-eluting stents and the risk of late thrombosis. N Engl J Med. 2007;356:981–984
  5. Marzocchi A, Saia F, Piovaccari G, Manari A, Aurier E, Benassi A, et al. Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry. Circulation. 2007;115:3181–3188
  6. Liistro F, Colombo A. Late acute thrombosis after paclitaxel eluting stent implantation. Heart. 2001;86:262–264
  7. Kerner A, Gruberg L, Kapeliovich M, Grenadier E. Late stent thrombosis after implantation of a sirolimus-eluting stent. Catheter Cardiovasc Interv. 2003;60:505–508
  8. Pasceri V, Pelliccia F, Cianfrocca C, Pristipino C, Santini M, Richichi G. Very late thrombosis after sirolimus-eluting stent implantation. J Cardiovasc Med. 2006;7:438–442
  9. Biondi-Zoccai GG, Lotrionte M, Agostoni P, Abbate A, Fusaro M, Burzotta F, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J. 2006;27:2667–2674
  10. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356:1020–1029
  11. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined: a consensus document of the joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36:959–969
  12. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, et al. Clopidogrel use and long-term clinical outcome after drug-eluting stent implantation. JAMA. 2007;297:159–168
  13. Beohar N, Davidson CJ, Kip KE, Goodreau L, Vlachos HA, Meyers SN, et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA. 2007;297:1992–2000
  14. Doyle B, Rihal CS, O'Sullivan CJ, Lennon RJ, Wiste HJ, Bell M, et al. Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. Circulation. 2007;116:2391–2398
  15. Choi S-H, Prasad A, Tsimikas S. The evolution of thienopyridine therapy. J Am Coll Cardiol. 2008;51:2228–2229
  16. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug eluding stents. JAMA. 2005;293:2126–2130
  17. Roy P, Bonello L, Torguson R, Okabe T, Pinto Slottow TL, Steinberg DH, et al. Temporal relation between clopidogrel cessation and stent thrombosis after drug-eluting stent implantation. Am J Cardiol. 2009;103:801–805
  18. Park DW, Yun SC, Lee SW, Kim YH, Lee CW, Hong MK, et al. Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent: data from an observational cohort study of drug-eluting versus bare-metal stents. J Am Coll Cardiol Intv. 2008;1:494–503
  19. Pfistaer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48:2584–2591
  20. Spertus JA, Kettelkamp R, Vance C, Decker B, Jones PG, Rumsfeld JS, et al. Prevalence, predictors and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER Registry. Circulation. 2006;113:2803–2809
  21. Dean J, Yujie Z, Yingxin Z, Yuyang L, Yonghe G, Wanjun C, et al. Prolonged dual antiplatelet therapy improves clinical outcomes in high-risk patients implanted with sirolimus-eluting stents. Clin Cardiol. 2009;32:164–168
  22. Angiolillo DJ. Variability in responsiveness to oral antiplatelet therapy. Am J Cardiol. 2009;103(suppl):27A–34A

PII: S0002-9149(09)01323-X

doi: 10.1016/j.amjcard.2009.07.002

American Journal of Cardiology
Volume 104, Issue 10 , Pages 1357-1361 , 15 November 2009

Article Tools

* Image Usage & Resolution